Dr. Robert A. Hozman, M.D.

Medicare patients and services

Medicare patients, 2024

361

Services billed

1,364

Patients’ average age

72

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 424 payments worth $18,725 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Illinois →

Industry-funded research

Named as a principal investigator on 23 industry-funded studies in 2025, from 9 companies. The companies reported $413,377 in research payments for these studies, mostly to the institutions running them.

• ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)?
  Janssen Research & Development, LLC
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
  UCB SA · Completed · NCT06624228
• A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Us…
  Takeda Pharmaceuticals U.S.A., Inc.
• A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1)
  E.r. Squibb & Sons, L.l.c.
• A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis
  Janssen Research & Development, LLC
• A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
  AbbVie Inc. · Active, not recruiting · NCT03671148
• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
  AbbVie Inc. · Recruiting · NCT06865105
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previo…
  E.r. Squibb & Sons, L.l.c.
• A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
  AbbVie Inc. · Completed · NCT04169373
• M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Rheumatology clinicians in Skokie

• Erin Arnold, MD
• William Arnold, MD
• John T. Berry, D.O.
• Ximena Y. Chavez, M.D.
• Justin B. Gan, M.D.
• Allan Pilloff, M.D.